Flyte Aviation, Inc.
Close on Oct 19, 2026
- Market cap
- $2.26M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 13, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Oct 13, 2026 | After market close | $2.15M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 18, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 31, 2026 | After market close | $238.00K | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 14, 2025 | After market close | $226.00K | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | After market close | $212.00K | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 1, 2025 | After market close | $149.00K | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | After market close | $96.00K | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 3, 2024 | After market close | $94.84K | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 2, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 11, 2024 | After market close | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Dec 18, 2023 | After market close | – | – | – |
Press releases
Announcements Flyte Aviation filed with the SEC
Flyte Aviation Partners with The Philadelphia 76ers
Regulation FD disclosure · EX-99.1 to Form 8-K
Flyte Aviation Reports Record Preliminary Third Quarter Revenue of $2.15 Million, Up 110% Quarter Over Quarter
Results of operations · EX-99.1 to Form 8-K
Flyte Aviation Launches Under NYSE American Ticker “ VJET ”
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CATHETER PRECISION REPORTS 200% REVENUE GROWTH AND COMPLETES TRANSFORMATIVE FLYTE ACQUISITION
Results of operations · EX-99.1 to Form 8-K
Catheter Precision Reports 2025 Results and Updates on Strategic Expansion
Results of operations · EX-99.1 to Form 8-K
Catheter Precision, Inc. Secures up to $36.5 Million in Strategic Institutional Financing to Accelerate Growth
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Catheter Precision (VTAK) Reports Third Quarter and First Nine Months 2025 Results of Operations
Results of operations · EX-99.1 to Form 8-K
Catheter Precision Receives Approval for LockeT in the United Kingdom
Other events · EX-99.1 to Form 8-K
Catheter Precision, Inc. Reports Results of Operations for Second Quarter 2025
Results of operations · EX-99.1 to Form 8-K
Catheter Precision (VTAK) Anticipates Highest LockeT Sales to Date in Q2 2025
Other events · EX-99.1 to Form 8-K
Catheter Precision, Inc. Announces First Quarter 2025 Update and Financial Results
Results of operations · EX-99.1 to Form 8-K
Catheter Precision, Inc. Announces Fourth Quarter and Full Year 2024 Update and Financial Results
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Catheter Precision, Inc. Announces Third Quarter Update and Financial Results
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE DATED OCTOBER 25, 2024.
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Catheter Precision, Inc. Announces Pricing of $3.1 Million Underwritten Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Catheter Precision, Inc. Announces Closing of $3.6 Million Underwritten Public Offering and Exercise of Overallotment Option
Material agreement · Other events · EX-99.2 to Form 8-K
Catheter Precision, Inc. (NYSE American: VTAK) Reports Q2 2024 Highlights and Operational Performance Report.
Results of operations · EX-99.1 to Form 8-K
Catheter Precision, Inc. (NYSE American: VTAK) Reports Preliminary Unaudited Revenue for the Second Quarter and Six Months Ended June 30, 2024
Results of operations · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Catheter Precision, Inc. (NYSE American: VTAK) Reports Q1 2024 Highlights and Operational Performance Report.
Results of operations · EX-99.1 to Form 8-K
Catheter Precision, Inc. (NYSE American: VTAK) Releases Operational Performance Report, Q4 and Annual 2023 Financials for Year Ending December 31, 2023
Results of operations · EX-99.1 to Form 8-K
CATHETER PRECISION, INC. (VTAK) Reports Unaudited Preliminary Fourth Quarter and Full Year 2023 Results
Results of operations · EX-99.1 to Form 8-K
CATHETER PRECISION, INC. Reports Third Quarter Results of Operations and Filing of Third Quarter 10-Q
Results of operations · EX-99.1 to Form 8-K
CATHETER PRECISION, INC. Reports Second Quarter Results of Operations
Results of operations · EX-99.1 to Form 8-K
Ra Medical Systems Announces First Quarter Results
Results of operations · EX-99.1 to Form 8-K
Ra Medical Systems Announces Delayed 10-Q Filing
Results of operations · Other events · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED ON MAY 16, 2023
Results of operations · Other events · EX-99.1 to Form 8-K
CATHETER PRECISION INC.’S Management's Discussion and Analysis of Financial Condition and Results of Operations
Other events · EX-99.3 to Form 8-K/A
December 31, 2022 and 2021
Other events · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS
Other events · EX-99.2 to Form 8-K
CATHETER PRECISION INC.’S Management's Discussion and Analysis of Financial Condition and Results of Operations
Other events · EX-99.3 to Form 8-K
Ra Medical Systems Completes Merger with Catheter Precision
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Ra Medical Systems Regains Compliance with NYSE American Continued Listing Standards
Other events · EX-99.1 to Form 8-K
Catheter Precision’s VIVO™ System Used in More Than 800 Procedures in Leading U.S. and European Hospitals
Other events · EX-99.1 to Form 8-K
Catheter Precision’s VIVO™ Systems Used in More Than 20 Procedures at NYU Langone Hospital
Other events · EX-99.1 to Form 8-K
Ra Medical Systems Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Ra Medical Systems Raises $7.6 Million Through Completed At-The-Market Facility
Other events · EX-99.1 to Form 8-K
Catheter Precision Files a Method-of-Use U.S. Patent Application for its VIVO ™ Technology
Other events · EX-99.1 to Form 8-K